Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering

Core Viewpoint - Dianthus Therapeutics, Inc. has announced the pricing of an upsized underwritten public offering of 7,313,582 shares of common stock at $81.00 per share, aiming to raise approximately $625 million before expenses [1][2]. Group 1: Offering Details - The offering includes pre-funded warrants for certain investors to purchase up to 402,468 shares at a price of $80.999 per warrant, with an exercise price of $0.001 per share [1]. - The offering is expected to close on March 12, 2026, subject to customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 1,157,407 shares at the public offering price [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to advance clinical and preclinical development activities, commercial readiness, working capital, and general corporate purposes [2]. Group 3: Regulatory Information - The offering is made pursuant to a shelf registration statement filed with the SEC, which was declared effective on January 30, 2026 [3]. - A preliminary prospectus supplement and accompanying prospectus have been filed with the SEC and are available on their website [3]. Group 4: Company Overview - Dianthus Therapeutics is a clinical-stage biotechnology company focused on developing next-generation therapies for severe autoimmune diseases [5]. - The company is based in New York City and Waltham, Massachusetts, and is led by an experienced team of biotech and pharma executives [5].